360 related articles for article (PubMed ID: 21859830)
1. Eribulin mesylate.
Jain S; Vahdat LT
Clin Cancer Res; 2011 Nov; 17(21):6615-22. PubMed ID: 21859830
[TBL] [Abstract][Full Text] [Related]
2. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
McBride A; Butler SK
Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
[TBL] [Abstract][Full Text] [Related]
3. Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer.
Mani S; Swami U
Drugs Today (Barc); 2010 Sep; 46(9):641-53. PubMed ID: 20967296
[TBL] [Abstract][Full Text] [Related]
4. Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer.
Cortes J; Lorca R
Future Oncol; 2011 Mar; 7(3):355-64. PubMed ID: 21375468
[TBL] [Abstract][Full Text] [Related]
5. Eribulin mesylate for the treatment of breast cancer.
Cigler T; Vahdat LT
Expert Opin Pharmacother; 2010 Jun; 11(9):1587-93. PubMed ID: 20450446
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.
O'Sullivan Coyne G; Walsh J; Kelly CM
Expert Opin Drug Saf; 2012 Jul; 11(4):643-50. PubMed ID: 22694309
[TBL] [Abstract][Full Text] [Related]
7. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
Scarpace SL
Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
[TBL] [Abstract][Full Text] [Related]
8. Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.
Polastro L; Aftimos PG; Awada A
Expert Rev Anticancer Ther; 2014 Jun; 14(6):649-65. PubMed ID: 24852360
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
[TBL] [Abstract][Full Text] [Related]
10. Eribulin mesylate in breast cancer.
Verdaguer H; Morilla I; Urruticoechea A
Womens Health (Lond); 2013 Nov; 9(6):517-26. PubMed ID: 24161305
[TBL] [Abstract][Full Text] [Related]
11. Eribulin therapy for the treatment of patients with advanced soft tissue sarcoma.
Seetharam M; Kolla KR; Chawla SP
Future Oncol; 2018 Jul; 14(16):1531-1545. PubMed ID: 29411654
[TBL] [Abstract][Full Text] [Related]
12. Eribulin mesylate for the treatment of late-stage breast cancer.
Gourmelon C; Frenel JS; Campone M
Expert Opin Pharmacother; 2011 Dec; 12(18):2883-90. PubMed ID: 22087618
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
Cortes J; Vahdat L; Blum JL; Twelves C; Campone M; Roché H; Bachelot T; Awada A; Paridaens R; Goncalves A; Shuster DE; Wanders J; Fang F; Gurnani R; Richmond E; Cole PE; Ashworth S; Allison MA
J Clin Oncol; 2010 Sep; 28(25):3922-8. PubMed ID: 20679609
[TBL] [Abstract][Full Text] [Related]
14. Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund.
Ramaswami R; O'Cathail SM; Brindley JH; Silcocks P; Mahmoud S; Palmieri C
Future Oncol; 2014 Feb; 10(3):363-76. PubMed ID: 24367990
[TBL] [Abstract][Full Text] [Related]
15. Eribulin: a novel cytotoxic chemotherapy agent.
Preston JN; Trivedi MV
Ann Pharmacother; 2012 Jun; 46(6):802-11. PubMed ID: 22619477
[TBL] [Abstract][Full Text] [Related]
16. Eribulin in Cancer Treatment.
Swami U; Shah U; Goel S
Mar Drugs; 2015 Aug; 13(8):5016-58. PubMed ID: 26262627
[TBL] [Abstract][Full Text] [Related]
17. Eribulin mesylate.
Huyck TK; Gradishar W; Manuguid F; Kirkpatrick P
Nat Rev Drug Discov; 2011 Mar; 10(3):173-4. PubMed ID: 21358731
[No Abstract] [Full Text] [Related]
18. Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
Aseyev O; Ribeiro JM; Cardoso F
Expert Opin Pharmacother; 2016; 17(4):589-600. PubMed ID: 26809667
[TBL] [Abstract][Full Text] [Related]
19. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
Cortes J; Montero AJ; Glück S
Cancer Treat Rev; 2012 Apr; 38(2):143-51. PubMed ID: 21550727
[TBL] [Abstract][Full Text] [Related]
20. Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next?
Aftimos P; Awada A
Adv Ther; 2011 Nov; 28(11):973-85. PubMed ID: 22020735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
